Unity Biotechnology

Unity Biotechnology is a startup biotechnology company that develops drugs which target senescent cells.[1][2][3][4][5][6][7]

Unity Biotechnology
TypePublic
NASDAQ: UBX
Russell 2000 Index component
IndustryBiotechnology, Pharmaceutical
PredecessorForge, Inc.
Founded2011 (2011) in California, United States of America
FoundersJudith Campisi, Jan van Deursen, Nathaniel “Ned” David, Daohong Zhou
Headquarters
South San Francisco, California
,
United States of America
Number of employees
70 (2018)
Websiteunitybiotechnology.com

The company's products in development include UBX1325 that targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 1 clinical trials for diabetic macular edema as of October 2020), UBX0101, targeting knee osteoarthritis (in Phase I clinical trials as of June 2018), and UBX1967, a preclinical product targeting ophthalmologic diseases.[8][9][10] All are senolytic medicines.

On May 3, 2018, the company went public on the Nasdaq exchange, raising $85 million at a market capitalization of $700 million.[11][9] Unity Biotechnology shares dropped over 60 per cent on August 17, 2020 after the company reported disappointing results from a clinical trial involving its lead drug candidate, UBX0101 in patients with moderate-to-severe painful osteoarthritis.[12]

See also

References
  1. Brueck, Hilary (3 February 2016). "Mayo Clinic Taps Silicon Valley to Help People Age Gracefully". Fortune. Retrieved 19 February 2018.
  2. Detrixhe, John (21 February 2018). "Crypto millionaires are funding research to reverse the aging process". Quartz (publication). Retrieved 19 February 2018.
  3. Herkewitz, William (19 February 2018). "Scientists Can Now Radically Expand the Lifespan of Mice—and Humans May Be Next". Popular Mechanics. Retrieved 19 February 2018.
  4. Ramsey, Lydia (10 November 2016). "A biotech startup that aims to rid our bodies of cells related to aging just got a big investment". Business Insider. Retrieved 19 February 2018.
  5. Scudellari, Megan (25 February 2017). "To Stay Young, Kill Zombie Cells". Scientific American. Retrieved 19 February 2018.
  6. Greenfieldboyce, Nell (3 February 2016). "Boosting Life Span By Clearing Out Cellular Clutter". Retrieved 19 February 2018.
  7. Baker, Darren (11 February 2016). "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan". Nature. 530 (7589): 184–189. doi:10.1038/nature16932. PMC 4845101. PMID 26840489.
  8. "S-1". www.sec.gov. Retrieved 2018-10-12.
  9. "Longevity Company Unity Biotechnology Stocks Soared After CEO Talks to CNBC | BioSpace". BioSpace. Retrieved 2018-10-12.
  10. "Unity Biotechnology to focus on senolytic programs in ophthalmology, neurology". www.healio.com. Retrieved 2020-12-08.
  11. CNBC (2018-05-02). "UNITY Biotechnology, Inc. Announces Pricing of Initial Public Offering of Common Stock". CNBC. Retrieved 2018-10-12.
  12. "Buzzy anti-aging biotech Unity drops leading program after flop, shares in freefall". 2020-08-17.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.